Dropyal 0.015% 20×0.65 ml eye drops solution

In ottemperanza all'articolo 118 “autorizzazione della pubblicità presso il pubblico” del decreto legislativo 24 aprile 2006, numero 219

INDICATIONS

Dry eye ocular syndromes. Moisturizing and lubricating the cornea and conjunctiva. Valid aid in the use of contact lenses.

ACTIVE INGREDIENTS

100 ml contain: Active ingredient: hyaluronic acid sodium salt 0.015 g For excipients see paragraph 6.1.

EXCIPIENTS

Carboxypolymethylene; glycerol, distilled water.

CONTRAINDICATIONS AND SIDE EFFECTS

Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.

DOSAGE

Dosage 1–2 drops four times or more/day, as directed by the doctor. Method of administration Open a sterile single-dose microvial by rotating the upper segment of the sterile microvial, instill the number of drops according to the indicated dosage into the lower conjunctival fornix. After opening and after the first instillation, close the vial by pressing the capsule located under the flap on the neck. The residue can be used no later than 6 hours after opening, as long as it is stored in a suitable environment. To avoid contamination, take care that the dropper and the microdoser capsule do not come into contact with the eyes or other non-sterile surfaces. Instructions for use To use the single-dose microvial, carry out the following operations: 1) Detach a vial from the strip 2) Shake the nozzle to free it from the liquid. 3) Open the single-dose vial by rotating the flap and simultaneously pulling. Hold the flap in one hand. 4) Exerting moderate pressure on the walls of the single-dose vial with the other hand, slowly release the medicine in drops in the prescribed dose.

CONSERVATION

Store at a temperature not exceeding 30°C.

WARNINGS

To avoid contamination, the microvial and the capsule, once separated, must not come into direct contact with the eyes or other surfaces.

INTERACTIONS

No interactions have ever been reported with the use of other systemic or topical drugs.

SIDE EFFECTS

In rare cases, slight transient burning upon instillation. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system www.agenziafarmaco.gov.it/it/responsabili.

OVERDOSE

No cases of overdose have ever been reported.

PREGNANCY AND BREASTFEEDING

No known contraindications.

EFFECTS ON DRIVING ABILITY

It does not interfere with driving ability or the use of machines.